vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and EyePoint, Inc. (EYPT). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $619.0K, roughly 100.4× EyePoint, Inc.). Cytek Biosciences, Inc. runs the higher net margin — -70.9% vs -10922.3%, a 10851.4% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -94.7%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-66.0M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -77.0%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
CTKB vs EYPT — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $619.0K |
| Net Profit | $-44.1M | $-67.6M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | -11364.3% |
| Net Margin | -70.9% | -10922.3% |
| Revenue YoY | 8.1% | -94.7% |
| Net Profit YoY | -557.1% | -63.3% |
| EPS (diluted) | — | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $619.0K | ||
| Q3 25 | $52.3M | $966.0K | ||
| Q2 25 | $45.6M | $5.3M | ||
| Q1 25 | $41.5M | $24.5M | ||
| Q4 24 | $57.5M | $11.6M | ||
| Q3 24 | $51.5M | $10.5M | ||
| Q2 24 | $46.6M | $9.5M | ||
| Q1 24 | $44.9M | $11.7M |
| Q4 25 | $-44.1M | $-67.6M | ||
| Q3 25 | $-5.5M | $-59.7M | ||
| Q2 25 | $-5.6M | $-59.4M | ||
| Q1 25 | $-11.4M | $-45.2M | ||
| Q4 24 | $9.6M | $-41.4M | ||
| Q3 24 | $941.0K | $-29.4M | ||
| Q2 24 | $-10.4M | $-30.8M | ||
| Q1 24 | $-6.2M | $-29.3M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | 93.0% | ||
| Q2 24 | 54.6% | 85.2% | ||
| Q1 24 | 51.3% | 93.5% |
| Q4 25 | -9.0% | -11364.3% | ||
| Q3 25 | -17.6% | -6420.8% | ||
| Q2 25 | -23.3% | -1166.8% | ||
| Q1 25 | -36.1% | -199.7% | ||
| Q4 24 | 5.2% | -390.4% | ||
| Q3 24 | -8.2% | -311.2% | ||
| Q2 24 | -18.3% | -364.5% | ||
| Q1 24 | -23.9% | -285.2% |
| Q4 25 | -70.9% | -10922.3% | ||
| Q3 25 | -10.5% | -6183.4% | ||
| Q2 25 | -12.2% | -1114.3% | ||
| Q1 25 | -27.5% | -184.8% | ||
| Q4 24 | 16.8% | -357.3% | ||
| Q3 24 | 1.8% | -279.0% | ||
| Q2 24 | -22.4% | -325.3% | ||
| Q1 24 | -13.8% | -250.6% |
| Q4 25 | — | $-0.82 | ||
| Q3 25 | — | $-0.85 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-0.65 | ||
| Q4 24 | — | $-0.65 | ||
| Q3 24 | — | $-0.54 | ||
| Q2 24 | — | $-0.58 | ||
| Q1 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $306.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $306.1M |
| Total Assets | $461.5M | $364.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $306.1M | ||
| Q3 25 | $93.3M | $204.0M | ||
| Q2 25 | $75.5M | $255.7M | ||
| Q1 25 | $95.3M | $318.2M | ||
| Q4 24 | $98.7M | $370.9M | ||
| Q3 24 | $162.3M | $253.8M | ||
| Q2 24 | $177.9M | $280.2M | ||
| Q1 24 | $168.8M | $299.3M |
| Q4 25 | $341.7M | $306.1M | ||
| Q3 25 | $378.6M | $200.2M | ||
| Q2 25 | $377.6M | $246.0M | ||
| Q1 25 | $379.6M | $298.4M | ||
| Q4 24 | $395.7M | $336.5M | ||
| Q3 24 | $385.5M | $218.7M | ||
| Q2 24 | $389.1M | $228.3M | ||
| Q1 24 | $392.6M | $249.9M |
| Q4 25 | $461.5M | $364.0M | ||
| Q3 25 | $494.9M | $251.7M | ||
| Q2 25 | $493.3M | $301.1M | ||
| Q1 25 | $482.6M | $362.6M | ||
| Q4 24 | $499.5M | $418.5M | ||
| Q3 24 | $491.2M | $300.9M | ||
| Q2 24 | $483.7M | $324.2M | ||
| Q1 24 | $492.1M | $329.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-65.0M |
| Free Cash FlowOCF − Capex | $-1.8M | $-66.0M |
| FCF MarginFCF / Revenue | -2.9% | -10667.7% |
| Capex IntensityCapex / Revenue | 1.6% | 159.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $-243.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-65.0M | ||
| Q3 25 | $-3.9M | $-59.4M | ||
| Q2 25 | $108.0K | $-62.6M | ||
| Q1 25 | $-125.0K | $-53.1M | ||
| Q4 24 | $2.0M | $-35.8M | ||
| Q3 24 | $13.2M | $-39.0M | ||
| Q2 24 | $6.2M | $-20.2M | ||
| Q1 24 | $4.0M | $-31.2M |
| Q4 25 | $-1.8M | $-66.0M | ||
| Q3 25 | $-4.6M | $-60.2M | ||
| Q2 25 | $-1.5M | $-63.8M | ||
| Q1 25 | $-974.0K | $-53.4M | ||
| Q4 24 | $1.1M | $-36.2M | ||
| Q3 24 | $12.2M | $-40.6M | ||
| Q2 24 | $5.2M | $-21.1M | ||
| Q1 24 | $3.4M | $-32.4M |
| Q4 25 | -2.9% | -10667.7% | ||
| Q3 25 | -8.7% | -6226.9% | ||
| Q2 25 | -3.2% | -1196.5% | ||
| Q1 25 | -2.3% | -218.4% | ||
| Q4 24 | 1.9% | -312.7% | ||
| Q3 24 | 23.7% | -385.8% | ||
| Q2 24 | 11.0% | -222.4% | ||
| Q1 24 | 7.6% | -277.0% |
| Q4 25 | 1.6% | 159.3% | ||
| Q3 25 | 1.3% | 82.6% | ||
| Q2 25 | 3.5% | 22.9% | ||
| Q1 25 | 2.0% | 1.1% | ||
| Q4 24 | 1.6% | 3.3% | ||
| Q3 24 | 2.0% | 15.0% | ||
| Q2 24 | 2.3% | 9.5% | ||
| Q1 24 | 1.3% | 10.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
EYPT
Segment breakdown not available.
